201 related articles for article (PubMed ID: 25576762)
1. Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: a retrospective cohort study.
Alagkiozidis I; Grossman A; Tang NZ; Weedon J; Mize B; Salame G; Lee YC; Abulafia O
Int J Surg; 2015 Feb; 14():61-6. PubMed ID: 25576762
[TBL] [Abstract][Full Text] [Related]
2. Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: A retrospective cohort study.
Alagkiozidis I; Weedon J; Grossman A; Wang P; Mize B; Wilson K; Shah T; Economos K; Salame G; Abulafia O; Lee YC
Int J Surg; 2015 Dec; 24(Pt A):9-13. PubMed ID: 26476418
[TBL] [Abstract][Full Text] [Related]
3. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
[TBL] [Abstract][Full Text] [Related]
4. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
5. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
6. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma.
Tanner EJ; Leitao MM; Garg K; Chi DS; Sonoda Y; Gardner GJ; Barakat RR; Jewell EL
Gynecol Oncol; 2011 Dec; 123(3):548-52. PubMed ID: 21945551
[TBL] [Abstract][Full Text] [Related]
7. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
Bristow RE; Duska LR; Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
[TBL] [Abstract][Full Text] [Related]
8. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR
Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590
[TBL] [Abstract][Full Text] [Related]
10. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
11. Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival.
Rajkumar S; Nath R; Lane G; Mehra G; Begum S; Sayasneh A
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():26-31. PubMed ID: 30639953
[TBL] [Abstract][Full Text] [Related]
12. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma.
Shih KK; Yun E; Gardner GJ; Barakat RR; Chi DS; Leitao MM
Gynecol Oncol; 2011 Sep; 122(3):608-11. PubMed ID: 21664663
[TBL] [Abstract][Full Text] [Related]
13. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
[TBL] [Abstract][Full Text] [Related]
15. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan.
Eto T; Saito T; Kasamatsu T; Nakanishi T; Yokota H; Satoh T; Nogawa T; Yoshikawa H; Kamura T; Konishi I
Gynecol Oncol; 2012 Nov; 127(2):338-44. PubMed ID: 22910693
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
18. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
19. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
Chambers LM; Jia X; Rose PG; AlHilli M
Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
[TBL] [Abstract][Full Text] [Related]
20. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
